Please ensure Javascript is enabled for purposes of website accessibility

Why Juno Therapeutics Fell 11% Today

By Brian Orelli, PhD - Sep 21, 2015 at 5:44PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors are spooked about drug pricing.

What's happening: Juno Therapeutics (JUNO) was doing just fine this morning, trading slightly below where it closed on Friday, until just after 11 a.m. Eastern when Democrat Presidential candidate Hillary Clinton sent out this tweet.

Price gouging like this in the specialty drug market is outrageous. Tomorrow I'll lay out a plan to take it on. -H

— Hillary Clinton (@HillaryClinton) September 21, 2015

Like many other biotechs, Juno Therapeutics fell on the news throughout the day, eventually ending down a hair below 11%.

Why it's happening: Juno Therapeutics was down more than the SPDR S&P Biotech ETF (XBI), which slipped just 5.4%, because of the type of drugs the biotech is developing. Juno's CAR-T therapeutics require the removal of a cancer patient's immune cells, selection and activation of the cells, and gene transfer to train the cells to attack the patient's tumor. At that point, the cells are grown in an incubator until there are enough to put back into the patient.

Source: Juno Therapeutics.

This is a personalized process for each patient; therefore, the company is going to have to charge a lot to recoup the manufacturing cost. CAR-T therapeutics aren't going to have the typical high margins that come with most pharmaceutical drugs. If the government puts pricing controls on drugs, it may be difficult for Juno Therapeutics, and the rest of the companies developing CAR-T therapeutics, to profit from the therapies if the drugs are eventually approved by the Food and Drug Administration.

Of course, a plan by a Presidential candidate is far from a law. And later in the day, Reuters reported that Clinton's plan will include a cap on patients' monthly out-of-pocket expenses for specialty drugs, which would be less of an issue for drugmakers than a cap on the price companies could charge insurance companies.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Juno Therapeutics, Inc. Stock Quote
Juno Therapeutics, Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.